https://thescriptpad.com/articles/medicare-2027-fee-schedule-conversion-factor-g2211-modifier.htmlThe Script Paden2026-10-11T09:30:00-04:00Medicare's 2027 Fee Schedule Would Cut the Conversion Factor and Turn G2211 Into a Percentage Modifier. Model It Before the Final Rule. https://thescriptpad.com/articles/2027-medicare-advantage-star-ratings-what-practices-should-know.htmlThe Script Paden2026-10-11T09:20:00-04:00The 2027 Medicare Advantage Star Ratings Are Out. New Drug Safety Measures Will Reach Your Prescribing. https://thescriptpad.com/articles/fda-approves-mavacamten-for-children-with-obstructive-hcm.htmlThe Script Paden2026-10-11T09:10:00-04:00FDA Approves Mavacamten for Children With Symptomatic Obstructive HCM. The Label Starts at 30 Kilograms. https://thescriptpad.com/articles/fda-approves-atezolizumab-adjuvant-stage-iii-dmmr-colon-cancer.htmlThe Script Paden2026-10-11T09:00:00-04:00FDA Approves Atezolizumab With Chemotherapy as Adjuvant Therapy for Stage III dMMR Colon Cancer https://thescriptpad.com/articles/fda-approves-belzutifan-lenvatinib-clear-cell-rcc.htmlThe Script Paden2026-10-11T08:45:00-04:00FDA Approves Belzutifan Plus Lenvatinib for Advanced Clear Cell Kidney Cancer After a PD-1 Inhibitor. Overall Survival Did Not Reach Significance. https://thescriptpad.com/articles/fda-approves-pritelivir-refractory-hsv.htmlThe Script Paden2026-10-11T08:30:00-04:00FDA Approves Pritelivir for Acyclovir-Refractory HSV in Immunocompromised Adults. Here Is What the Label Covers. https://thescriptpad.com/articles/fda-bayesian-trial-guidance-webinar-oct-14.htmlThe Script Paden2026-10-11T08:15:00-04:00FDA Holds a Webinar Oct. 14 on Its Bayesian Trial Guidance. Here Is How to Read the Trials It Covers. https://thescriptpad.com/articles/cms-final-ambulatory-specialty-model-participant-list.htmlThe Script Paden2026-10-11T08:00:00-04:00CMS Has Published the Final Ambulatory Specialty Model Participant List. Specialists Should Check It Before Jan. 1. https://thescriptpad.com/articles/fda-seeks-input-ibogaine-trial-design.htmlThe Script Paden2026-10-11T07:30:00-04:00The FDA Is Asking for Public Input on Ibogaine Trial Design. Comments Close Nov. 20.